Paratek slips into public market with Transcept buy
This article was originally published in Scrip
Paratek Pharmaceuticals gave up on trying to raise public capital for its Phase III antibiotic on its own in mid-2013, but found a way to list its shares in the US stock market in 2014 via a reverse merger with the flailing specialty pharma company Transcept Pharmaceuticals.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.